Vein Ablation Coverage: Reflux on Ultrasound, Not Bulging Veins

The short version

• The gap that pays: the covered regimen — consult → duplex ultrasound → ablation — bills ~$1,417–1,567 per leg to insurance; the identical ablation done cosmetically (no reflux) is ~$2,000–3,500 cash. Qualify the patient right; never bill a cosmetic ablation to insurance.
• Endovenous ablation is two code pairs by energy source — RF 36475/36476, laser 36478/36479 — covered only for symptomatic venous insufficiency with saphenous reflux on duplex ultrasound.
• The ultrasound does double duty: 93970/93971 proves the reflux that unlocks coverage AND bills as its own line (~$184) — the diagnostic anchor, distinct from the ablation.
• Ablation is not sclerotherapy. Sclero is an injection — cosmetic spider-vein sclero (36468) is a separate cash service, never a way to bill an ablation. Covered path also needs a failed 3-month compression trial first.

Endovenous ablation codes: RF (36475) vs laser (36478)

The first thing that goes wrong on a vein-ablation claim is the code pair. Endovenous ablation splits by energy source. Radiofrequency is 36475 for the first vein and 36476 for each additional vein in the same extremity. Laser is 36478 for the first and 36479 for each additional. They are not interchangeable.

Bill 36475 for a laser case and you’ve described the wrong procedure. The add-on codes (36476, 36479) also have their own rules per extremity, so the count has to match the operative note. Pick the pair that matches the device, then count the veins, then move to the part that actually decides coverage.

One distinction that trips up coding: ablation is not sclerotherapy. Ablation threads a catheter and closes the vein with heat — RF (36475/76) or laser (36478/79). Sclerotherapy is an injection — a sclerosant pushed into the vein — a separate service with separate codes. Cosmetic sclerotherapy of spider veins (36468) is a cash procedure; it is never a substitute for, or a way to bill, an ablation. Different mechanism, different code, different payer.

Saphenous reflux on duplex ultrasound: the coverage anchor

Coverage anchors on one finding: venous reflux, documented on duplex ultrasound. Payer policy wants the study to show incompetent valves and reflux in the treated vein, most often saphenous reflux, before it will authorize ablation. Visible bulging veins are the symptom; the ultrasound is the proof.

So the duplex study carries the claim. A leg full of ropey varicosities with no documented reflux is a cosmetic-looking claim. The same leg with a duplex showing saphenous reflux and matching symptoms is medical necessity. Get the ultrasound, document the reflux, and the claim has its spine.

The duplex does double duty, and both halves are billable. It is the diagnostic that proves the reflux coverage hinges on, and it is a paid line of its own — 93970 (complete bilateral, ~$184) or 93971 (unilateral/limited). It appears twice in a clean episode: the pre-treatment map that establishes necessity, and the post-treatment scan that confirms the vein closed. The scan anchors the claim; it is not an afterthought to it.

The conservative-therapy trial payers require

Even with reflux on the ultrasound, most payers want time on conservative therapy first. Commercial policy commonly requires a roughly three-month trial of compression stockings, documented as failed, before ablation is medically necessary.

Skip the trial and you’ve handed the payer its denial. Symptomatic varicose veins treated without the documented conservative trial are considered cosmetic by policy, regardless of the reflux. Start the compression, document the dates and the failure, and the ablation reads as the next step instead of the first reach.

Worth knowing for appeals: the specialty’s own guideline disagrees with the payers here. The joint SVS/AVF/AVLS varicose-vein guideline recommends against a mandatory conservative-therapy trial before intervention when axial reflux is documented — yet most payer LCDs still require the 3-month compression trial. You bill to the payer’s rule, not the guideline’s, but the gap is a legitimate lever in a medical-necessity appeal.

The vein regimen priced: covered pathway vs cash-pay ablation

A covered vein case is a regimen, not a single code: consult, then the duplex that proves reflux, then — after a documented conservative-therapy trial — the ablation, then a closure scan. At 2026 Medicare (non-facility, per leg):

Now the same ablation with no documented reflux — an asymptomatic or cosmetic leg. Not covered, billed to the patient in cash:

The twist most practices miss: cash pays more per leg than Medicare does (~$3,000 vs ~$1,567). So the money is not in forcing everything through insurance — it is in qualifying the patient correctly. Reflux and symptoms on the record: run the covered regimen and bill the payer. Purely cosmetic: a legitimate cash procedure at the higher price. What you cannot do is bill a cosmetic ablation to insurance — that is a false claim. (Cash range per GoodRx and MDsave.) Keeping that line clean is exactly what a disciplined billing operation is for.

Who renders the vein service — and how to staff the margin

A vein regimen splits across provider types, and that split is a margin lever — the who-save factor:

• Duplex ultrasound → a registered vascular technologist, not the physician. The tech runs the scan; the physician bills only the interpretation.
• Ablation → the physician for the high-RVU 36475, though APPs increasingly perform ablations under supervision where state scope allows (JVS-Venous, 2024).
• Cosmetic sclerotherapy and follow-ups → an APP or RN in many clinics — the fully delegable, cash-pay work.

The lever: keep the physician on the ablation, push the scan to the tech and the cosmetic injections to the APP/RN, and bill qualifying APP visits incident-to at 100% of the fee schedule instead of 85% under the APP’s own NPI. That is how a vein practice scales volume without adding physician hours.

The catch, and it has teeth: incident-to only pays the full rate when the supervision and established-plan-of-care conditions are actually met. The DOJ has settled multi-million-dollar False Claims Act cases against vein practices for improper supervision and billing. The who-save factor is real revenue — only when it is done exactly right, which is a revenue cycle job, not just a coding one.

But the who-save factor is a net number, not a free one — every role you delegate to carries a salary. Loaded cost (base plus benefits, payroll tax, and overhead) runs roughly 1.3× the figures below (BLS, 2025):

Delegation only nets margin when each seat clears its own loaded cost. The sonographer and the RN do that almost trivially. The APP is the real judgment call: at ~$180K loaded, an NP or PA earns their keep only when the schedule is full — incident-to at 100% helps, but it does not manufacture volume. The durable leverage is simpler than any of it: pull the physician off the $184 scan so they can run another $1,056 ablation. That swap, repeated, is the whole margin case — and it only holds if the staffing is sized to the volume, not bought ahead of it.

Documenting vein ablation for coverage

The ablation that clears carries four things: the duplex ultrasound showing reflux, the documented three-month compression trial that failed, the symptoms and CEAP clinical class, and prior authorization with the correct RF-or-laser code pair. The ultrasound is load-bearing; the trial is the gate.

Build it before the procedure. The reflux study and the conservative-trial dates have to predate the ablation, and most plans require predetermination. If the denials are stacking up on legitimately symptomatic, reflux-positive legs, our medical billing operation works the ultrasound documentation and the appeals behind it.

Frequently asked questions

This article explains how these codes tend to get paid — it is not coding, billing, or legal advice. Some of the codes here are bundled into the main procedure, or fall into grey areas that vary by payer. Before billing anything in a grey area, confirm it with your own coding and compliance team and the current guidance from the American Vein & Lymphatic Society (AVLS), Medicare (CMS), and AMA CPT. When in doubt, don’t bill it.